CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• The Role Of Peptones In Boosting Monoclonal Antibody Production

  Peptones have become a key tool in CHO cell bioprocessing, enhancing monoclonal antibody yield and quality.

• Chimeric Antigen Receptor Plasmid Production

  Parallel single-use bioreactor setups enable faster optimization, improved reproducibility, and smoother transition from development to production—supporting more efficient and consistent cell therapy workflows.

• Vial Adapter Transfer Device Compatibility With Cell Therapies

  Needles and syringes are commonly used to retrieve cell therapies from vials, posing the risk of needle stick injury. Explore the suitability of needle-free polycarbonate transfer devices.

• Streamline AAV-Based Gene Therapies With Off-The-Shelf Plasmids

  Standardized, well-characterized plasmids and streamlined platform processes can significantly accelerate viral vector development, improve consistency, and support scalable, high-quality gene therapy manufacturing.

• Simpler, Faster, Cheaper Advanced Therapy Manufacturing

  Discover how TFDF-based perfusion technology boosts lentiviral vector production by over 10-fold, slashes costs, and accelerates the commercialization of CAR-T and other advanced cell therapies.

• Navigating CMC Regulation For Plasmid DNA In Gene Therapy

  Explore how evolving regulatory pathways and CMC innovation are shaping the future of gene therapy and viral vector production, plus what to consider when selecting a CDMO partner.

• Monitoring Microbial Contamination Of Mammalian Cell Cultures

  Mammalian cells are widely used to produce complex processed molecules. Explore a system that effectively detects microbial contamination in mammalian cell cultures and utilizes a newly formulated lysis buffer.

• Lightning-Link^® Conjugation Kits: Consistent Performance On A Broad Scale

  Learn about labeling technology offering a transformative solution through direct antibody labeling without the need for post-conjugation purification, thereby mitigating antibody loss and ensuring reproducible results.

• Delivering Critical Therapies With Speed And Safety

  Faster approvals depend on treating regulation as part of development, not the finish line. See how early quality planning and strong agency communication can move therapies toward patients sooner.

• Enhancing AAV Production Performance And Economics

  Enzymatically produced dbDNA offers safer, faster, and more scalable AAV manufacturing by reducing costs, improving full capsid yields, and enabling high‑fidelity, bacteria‑free DNA production.